These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 36475694)

  • 21. From Repurposing to Redesign: Optimization of Boceprevir to Highly Potent Inhibitors of the SARS-CoV-2 Main Protease.
    Göhl M; Zhang L; El Kilani H; Sun X; Zhang K; Brönstrup M; Hilgenfeld R
    Molecules; 2022 Jul; 27(13):. PubMed ID: 35807537
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Structure-Based Design of a Dual-Targeted Covalent Inhibitor Against Papain-like and Main Proteases of SARS-CoV-2.
    Yu W; Zhao Y; Ye H; Wu N; Liao Y; Chen N; Li Z; Wan N; Hao H; Yan H; Xiao Y; Lai M
    J Med Chem; 2022 Dec; 65(24):16252-16267. PubMed ID: 36503248
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting SARS-CoV-2 Main Protease for Treatment of COVID-19: Covalent Inhibitors Structure-Activity Relationship Insights and Evolution Perspectives.
    La Monica G; Bono A; Lauria A; Martorana A
    J Med Chem; 2022 Oct; 65(19):12500-12534. PubMed ID: 36169610
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery of α-Ketoamide inhibitors of SARS-CoV-2 main protease derived from quaternized P1 groups.
    Huang Q; Quan B; Chen Y; Zhao X; Zhou Y; Huang C; Qiao J; Wang Y; Li Y; Yang S; Lei J; Li L
    Bioorg Chem; 2024 Feb; 143():107001. PubMed ID: 38101266
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Small-Molecule Thioesters as SARS-CoV-2 Main Protease Inhibitors: Enzyme Inhibition, Structure-Activity Relationships, Antiviral Activity, and X-ray Structure Determination.
    Pillaiyar T; Flury P; Krüger N; Su H; Schäkel L; Barbosa Da Silva E; Eppler O; Kronenberger T; Nie T; Luedtke S; Rocha C; Sylvester K; Petry MRI; McKerrow JH; Poso A; Pöhlmann S; Gütschow M; O'Donoghue AJ; Xu Y; Müller CE; Laufer SA
    J Med Chem; 2022 Jul; 65(13):9376-9395. PubMed ID: 35709506
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discovery of meisoindigo derivatives as noncovalent and orally available M
    Gao Q; Liu S; Zhou Y; Fan J; Ke S; Zhou Y; Fan K; Wang Y; Zhou Y; Xia Z; Deng X
    Eur J Med Chem; 2024 Jul; 273():116498. PubMed ID: 38762916
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discovery of Potent Pyrazoline-Based Covalent SARS-CoV-2 Main Protease Inhibitors.
    Moon P; Zammit CM; Shao Q; Dovala D; Boike L; Henning NJ; Knapp M; Spradlin JN; Ward CC; Wolleb H; Fuller D; Blake G; Murphy JP; Wang F; Lu Y; Moquin SA; Tandeske L; Hesse MJ; McKenna JM; Tallarico JA; Schirle M; Toste FD; Nomura DK
    Chembiochem; 2023 Jun; 24(11):e202300116. PubMed ID: 37069799
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Structure-Based Design of Potent Peptidomimetic Inhibitors Covalently Targeting SARS-CoV-2 Papain-like Protease.
    Wang Q; Chen G; He J; Li J; Xiong M; Su H; Li M; Hu H; Xu Y
    Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37239980
    [TBL] [Abstract][Full Text] [Related]  

  • 29. SARS-CoV-2 M
    Citarella A; Scala A; Piperno A; Micale N
    Biomolecules; 2021 Apr; 11(4):. PubMed ID: 33921886
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ebselen derivatives inhibit SARS-CoV-2 replication by inhibition of its essential proteins: PL
    Zmudzinski M; Rut W; Olech K; Granda J; Giurg M; Burda-Grabowska M; Kaleta R; Zgarbova M; Kasprzyk R; Zhang L; Sun X; Lv Z; Nayak D; Kesik-Brodacka M; Olsen SK; Weber J; Hilgenfeld R; Jemielity J; Drag M
    Sci Rep; 2023 Jun; 13(1):9161. PubMed ID: 37280236
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Allosteric inhibitors of the main protease of SARS-CoV-2.
    Samrat SK; Xu J; Xie X; Gianti E; Chen H; Zou J; Pattis JG; Elokely K; Lee H; Li Z; Klein ML; Shi PY; Zhou J; Li H
    Antiviral Res; 2022 Sep; 205():105381. PubMed ID: 35835291
    [TBL] [Abstract][Full Text] [Related]  

  • 32. AI-Driven Discovery of SARS-CoV-2 Main Protease Fragment-like Inhibitors with Antiviral Activity
    Saramago LC; Santana MV; Gomes BF; Dantas RF; Senger MR; Oliveira Borges PH; Ferreira VNDS; Dos Santos Rosa A; Tucci AR; Dias Miranda M; Lukacik P; Strain-Damerell C; Owen CD; Walsh MA; Ferreira SB; Silva-Junior FP
    J Chem Inf Model; 2023 May; 63(9):2866-2880. PubMed ID: 37058135
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High-throughput screening of SARS-CoV-2 main and papain-like protease inhibitors.
    Zang Y; Su M; Wang Q; Cheng X; Zhang W; Zhao Y; Chen T; Jiang Y; Shen Q; Du J; Tan Q; Wang P; Gao L; Jin Z; Zhang M; Li C; Zhu Y; Feng B; Tang B; Xie H; Wang MW; Zheng M; Pan X; Yang H; Xu Y; Wu B; Zhang L; Rao Z; Yang X; Jiang H; Xiao G; Zhao Q; Li J
    Protein Cell; 2023 Jan; 14(1):17-27. PubMed ID: 36726755
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In Silico Drug Repositioning to Target the SARS-CoV-2 Main Protease as Covalent Inhibitors Employing a Combined Structure-Based Virtual Screening Strategy of Pharmacophore Models and Covalent Docking.
    Vázquez-Mendoza LH; Mendoza-Figueroa HL; García-Vázquez JB; Correa-Basurto J; García-Machorro J
    Int J Mol Sci; 2022 Apr; 23(7):. PubMed ID: 35409348
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combining virtual screening with cis-/trans-cleavage enzymatic assays effectively reveals broad-spectrum inhibitors that target the main proteases of SARS-CoV-2 and MERS-CoV.
    Chang YJ; Le UNP; Liu JJ; Li SR; Chao ST; Lai HC; Lin YF; Hsu KC; Lu CH; Lin CW
    Antiviral Res; 2023 Aug; 216():105653. PubMed ID: 37321487
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dual Inhibitors of Main Protease (M
    Mondal S; Chen Y; Lockbaum GJ; Sen S; Chaudhuri S; Reyes AC; Lee JM; Kaur AN; Sultana N; Cameron MD; Shaffer SA; Schiffer CA; Fitzgerald KA; Thompson PR
    J Am Chem Soc; 2022 Nov; 144(46):21035-21045. PubMed ID: 36356199
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Danshensu inhibits SARS-CoV-2 by targeting its main protease as a specific covalent inhibitor and discovery of bifunctional compounds eliciting antiviral and anti-inflammatory activity.
    Wang R; Chen X; Li H; Chen X; Sun D; Yu D; Lu J; Xie Y; Zhang Q; Xu J; Zhang W; Chen H; Liu S; Chen L
    Int J Biol Macromol; 2024 Feb; 257(Pt 2):128623. PubMed ID: 38070810
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reckoning a fungal metabolite, Pyranonigrin A as a potential Main protease (M
    Rao P; Shukla A; Parmar P; Rawal RM; Patel B; Saraf M; Goswami D
    Biophys Chem; 2020 Sep; 264():106425. PubMed ID: 32663708
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of SARS-CoV-2 Main Protease Inhibitors from a Library of Minor Cannabinoids by Biochemical Inhibition Assay and Surface Plasmon Resonance Characterized Binding Affinity.
    Liu C; Puopolo T; Li H; Cai A; Seeram NP; Ma H
    Molecules; 2022 Sep; 27(18):. PubMed ID: 36144858
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Structure and inhibition of SARS-CoV-1 and SARS-CoV-2 main proteases by oral antiviral compound AG7404.
    Fàbrega-Ferrer M; Herrera-Morandé A; Muriel-Goñi S; Pérez-Saavedra J; Bueno P; Castro V; Garaigorta U; Gastaminza P; Coll M
    Antiviral Res; 2022 Dec; 208():105458. PubMed ID: 36336176
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.